Quarterly Activities and Appendix 4C Cash Flow Report
| Stock | Echoiq Ltd (EIQ.ASX) |
|---|---|
| Release Time | 30 Oct 2025, 4:20 p.m. |
| Price Sensitive | Yes |
Echo IQ reports Q3 2025 progress
- Commenced clinical validation study for EchoSolv HF with Mayo Clinic
- Echocardiogram processing via EchoSolv AS up 153% in Q3, further 58% increase in Oct
- Onboarded with ScImage, a US diagnostics workflow platform with 1,200 customers
- Appointed two senior US advisors to support regulatory and commercial expansion
Echo IQ Limited (ASX:EIQ) reported significant progress in the three-month period ended 30 September 2025. Key highlights included the commencement of a clinical validation study for the company's heart failure decision support software EchoSolv HF in collaboration with the Mayo Clinic Platform. This study is the final regulatory requirement prior to a formal FDA submission for EchoSolv HF in the US market. The company also saw a 153% increase in echocardiogram processing via its FDA-approved EchoSolv AS platform during the quarter, with a further 58% uplift in October. Echo IQ completed onboarding and integration with ScImage, a leading US diagnostics workflow management platform with over 1,200 customers, and appointed two senior US cardiology advisors - Dr Philippe Genereux and Dr Asif Ali - to support regulatory engagement, clinical validation, and commercial expansion. The company also made progress on international expansion, with negotiations advancing to finalize a distribution agreement in Europe. Looking ahead, Echo IQ is focused on completing the Mayo Clinic validation study, submitting EchoSolv HF to the FDA, and driving further US and global adoption of its technologies.
Echo IQ expects to complete the Mayo Clinic validation study and submit EchoSolv HF for FDA clearance in the coming weeks. The company is also focused on converting its established pipeline of US hospital groups, pharmaceutical companies and device manufacturers to increase uptake of EchoSolv in the US market.
Echo IQ remains focused on delivering key milestones in Q4 2025 and early 2026, including completing the EchoSolv HF validation study, finalizing the FDA submission, securing clearance for EchoSolv HF in the US, advancing a reimbursement strategy, converting its US pipeline, and expanding into international markets like the EU.